secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120267
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VK2735 oral Phase 1 shows up to 8.2% weight loss; Phase 2 data support monthly maintenance dosing
--------------------------------------------------------------------------------

- Oral VK2735 achieved up to 8.2% mean weight loss from baseline (6.8% placebo-adjusted) at 28 days.
- 100% of subjects on 100 mg oral VK2735 reached ≥5% weight loss vs. 0% placebo; GI events mostly mild.
- Phase 2 VENTURE: 94% of weight loss maintained 4 weeks post-final dose; supports once-monthly dosing.
- 78% of prediabetic patients on VK2735 shifted to normoglycemic over 13 weeks vs. 29% on placebo.
- Oral Phase 2 to start by year-end 2024; injectable Phase 3 design to be discussed with FDA this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024120267/0000950170-24-120267-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024120267/vktx-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120267

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer